They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of ... in phase 3 known as CagriSema, which is based on semaglutide ...

The firm sees a “reasonable” valuation at current share levels and views the upcoming CagriSema readout from Novo Nordisk (NVO) as a “positively skewed catalyst.” Published first on TheFly ...

The market overreacted to CagriSema trial results, causing a 20% stock drop, despite promising 22.7% weight loss results. I believe the market's reaction to CagriSema is disproportionate and doesn ...

During the relevant period, Novo Nordisk was conducting its highly anticipated Phase 3 study, REDEFINE-1, for CagriSema, an investigational drug developed for the treatment of obesity and type 2 ...

On December 20, 2024, Novo announced headline results for its REDEFINE-1 trial, which determined that the Company's CagriSema product had achieved a weight loss average of only 22.7% after 68 weeks.

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectation of at least 25% weight loss. The press release ...

CASE DETAILS: According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their "REDEFINE 1" trial, "a 68-week efficacy and safety trial ...

Supply constraints for its in- demand obesity drug Wegovy have affected the stock, along with disappointing results in a late-stage trial for its next generation obesity drug CagriSema.

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory submission expected early next year. The FDA approved ranibizumab ...

defendants created the false impression that they possessed reliable information pertaining to Novo Nordisk’s projected successful outcome of Novo Nordisk’s phase 3 CagriSema study on obesity ...